ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ATTO / news
SLBT (45) DNA (35) SLDB (26) FDMT (44) ⌘ Pro Terminal →

Why ATTO Stock slipped -0.92% Today — RQD Quant Desk Flash

$15.05 -0.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.00

Attovia Therapeutics Inc. (ATTO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $693.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATTO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATTO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Attovia Therapeutics Inc. (NASDAQ: ATTO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $15.05 (-0.92% 1D, market cap $693.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ATTO ranks #389 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATTO compare to SLBT and DNA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATTO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SLBT (SL Science Holding Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M) and DNA (Ginkgo Bioworks Holdings Inc. (Class A)) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $721.3M). Among the 5-stock peer group, ATTO leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATTO?
▼

Per ATTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002058707), Attovia Therapeutics Inc. generated $69.7M in revenue, $0 in net income, and $0 in free cash flow against $165.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $15.00 (-0.36%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 27.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (10)Whales (3)SEC (13)Macro (9)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$29 Bull$14 Base$11 Bear
📬 FREE ATTO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATTO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY ATTO SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 27.9% FCF Margin ($19.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$14.72-4.6% Next Q
Q2 (-2Q)
39
Grade E$14.04+6.8% Next Q
Q3 (-1Q)
41
Grade D$15.00+0.3% Next Q
Current
44
Grade D$15.05-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATTO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATTO currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.45) and Max Pain ($15.80) forces dealer call-delta covering toward $29.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATTO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ATTO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why ATTO Stock slipped -0.92% Today — RQD Quant Desk Flash

Attovia Therapeutics Inc. (ATTO) slipped -0.92% to $15.05, trading at 14% of its 52-week range ($12.94 – $28). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 14% of its 52-week range ($12.94 – $28) with RSI-14 at 43.5 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $15.05 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $19.4M annual free cash flow.
Live ATTO Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATTO)

  • ✓Walkthrough of ATTO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ATTO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.28%▼ DESCENDING CHANNEL
2026-11-03O $15.27H $15.27L $15.05C $15.05VOL 146.7K
RES: $16.38SUP: $9.79SMA50: $18.45SMA200: $18.91
$29.05$24.69$20.32$15.95$11.58RES $16.38SUP $9.79$15.052026-08-052026-08-262026-09-182026-10-122026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATTO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATTO Butterfly Map → + Track ATTO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ATTO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATTO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ATTO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATTO)

Health Care Rank #389 of 1015 ⚔️ SLBT vs ATTO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATTO vs. SLBT, DNA, SLDB, FDMT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Attovia Therapeutics Inc. (ATTO) ranks #389 by composite RQD confidence (44/100, grade D) and #396 by equity capitalization ($693.4M). Within this direct 5-issuer industry benchmark cohort, ATTO leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. SLBT currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with ATTO at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ATTO ACTIVE
Attovia Therapeutics Inc.
D 44/100 — — — -0.92% $693.4M Benchmark Subject
SLBT
SL Science Holding Limited
D 45/100 — — — +5.83% $672.9M /slbt-vs-atto →
DNA
Ginkgo Bioworks Holdings Inc. (Class A)
D- 35/100 — — -35.0% -12.13% $721.3M /dna-vs-atto →
SLDB
Solid Biosciences Inc.
E 26/100 — — -35.0% -3.23% $664.8M /sldb-vs-atto →
FDMT
4D Molecular Therapeutics Inc.
D 44/100 — — -28.3% -4.45% $657.4M /fdmt-vs-atto →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002058707 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Attovia Therapeutics Inc. (ATTO) reported GAAP revenue of $69.7M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ATTO closed FY2025 with $165.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $69.7M $0 — — $165.9M —

3. ATTO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATTO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Attovia Therapeutics Inc. (NASDAQ: ATTO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $15.05 (-0.92% 1D, market cap $693.4M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ATTO ranks #389 in composite RQD confidence.

How does ATTO compare to SLBT and DNA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATTO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SLBT (SL Science Holding Limited) holds a D grade (45/100 RQD, P/E N/A, ROIC —, cap $672.9M) and DNA (Ginkgo Bioworks Holdings Inc. (Class A)) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $721.3M). Among the 5-stock peer group, ATTO leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ATTO?

Per ATTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002058707), Attovia Therapeutics Inc. generated $69.7M in revenue, $0 in net income, and $0 in free cash flow against $165.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ATTO trading relative to its 50-day, 200-day, and 52-week technical levels?

ATTO last traded at $15.05 (-0.92% on volume of 154,904 shares), positioning the stock -18.43% below its 50-day simple moving average ($18.45) and -20.41% below its 200-day simple moving average ($18.91). Across its 52-week range of $12.94 to $28.00, ATTO sits at the 14.0% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.17 to $16.93).

Direct Sub-Reports: ATTO RQD Cockpit ATTO 12M Forecast ATTO Earnings & Move ATTO Dividends & DRIP ATTO Insiders & 13F ATTO Whale Options ATTO Profit Sankey ATTO News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

ATTO — Attovia Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Attovia Therapeutics Inc. (ATTO) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $15.05 (-0.92% 1D, market capitalization $693.4M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Attovia Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. It is classified in this industry with a market capitalization of $0.7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Attovia Therapeutics Inc. (ATTO) reported $69.7M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $165.9M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $12.94 – $28.00 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Second-order bottlenecks cannot be identified from the provided data.

  • Key Question #1: Can ATTO sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $69.7M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ATTO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ATTO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Attovia Therapeutics Inc. (ATTO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATTO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATTO Bull vs. Bear Conversation Board — What's Your Call at $15.05?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATTO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ATTO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $18.53 (+22.0%)
📌 Pinned Debate

Per the Roarable RQD rating, the forensic balance sheet pillar scores 13 / 20 with a Piotroski F-Score of 6/9, its strongest component.

Picked up a starter position in ATTO in my $100K Virtual Cash book at $15.19. Per the Roarable RQD rating, the forensic balance sheet pillar scores 13 / 20 with a Piotroski F-Score of 6/9, its strongest component.. Trading inside a $12.94–$28.00 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@MeanReversion_88 Shorting a 3/20 institutional whale-flow stock at $15.19 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $12.15 (-20.0%)
Spot @ $15.19

Per the Roarable RQD rating, the whale/13F flow pillar scores only 3 / 20, with ROIC and FCF yield both at 0%.

Careful chasing ATTO at $15.19. Per the Roarable RQD rating, the whale/13F flow pillar scores only 3 / 20, with ROIC and FCF yield both at 0%.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $12.15 on multiple compression.

LIVE TAPE